AI Article Synopsis
- - Tumor hypoxia significantly reduces the effectiveness of oxygen-dependent treatments like photodynamic therapy (PDT) and chemotherapy, prompting the need for innovative solutions.
- - A new nanoplatform (DOX/Met/BSA-HA-CDs) aims to tackle this issue by using carbon dots for imaging and metformin to boost oxygen levels and enhance treatment effectiveness.
- - Lab and animal studies show that these nanoparticles effectively lower oxygen consumption in tumors and improve cancer treatment outcomes, indicating strong potential for clinical application.
Article Abstract
Tumor hypoxia impedes the efficiencies of oxygen-dependent photodynamic therapy (PDT) and chemotherapy. Herein, we design a traceable nanoplatform (DOX/Met/BSA-HA-CDs) by reducing oxygen (O) consumption to overcome the hypoxia-caused cancer therapy. Carbon dots (CDs) are used not only as a PDT agent but also applied for in vivo traceable imaging. Metformin (Met), a potent antihyperglycemic agent, to improve tumor oxygenation and enhance the efficiencies of hypoxia-caused cancer therapy. In the hypoxic tumor microenvironment, Met was released more rapidly than DOX, which is advantageous for improving hypoxic cancer to exert a better therapeutic efficiency. Ex vivo immunofluorescence staining revealed that the DOX/Met/BSA-HA-CDs nanoparticles greatly reduce O consumption in tumor site. Followed by in vivo synergistic treatment achieved considerably enhanced cancer therapeutic efficiency. This system holds great clinical promise as a traceable imaging approach to guide the improvement of PDT and chemotherapy efficiencies through utilizing a simple, safe method improved hypoxic tumor microenvironment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.nano.2019.03.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!